DBV Technologies S.A. (DBVT) stock

DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 6/30

$11.43−0.45 (-3.79%)

Close on Nov 12, 2026Market cap $718.69MP/E –Yield –

DBV Technologies ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$144.07M.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$144.07M	–
FY2024	Dec 31, 2024	-$113.87M	–
FY2023	Dec 31, 2023	-$72.87M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$64.20M	–

Parsed from the XBRL in DBV Technologies's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on Jun 7, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing